3a-Methyl-6-(3-oxo-butyl)-1,2,4,5,9a,9b-hexahydro-3aH-9-oxa-cyclopenta[a]naphthalene-3,7-dione | 919788-02-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: 3a-Methyl-6-(3-oxo-butyl)-1,2,4,5,9a,9b-hexahydro-3aH-9-oxa-cyclopenta[a]naphthalene-3,7-dione
• 英文别名: 6a-methyl-4-(3-oxobutyl)-5,6,8,9,9a,9b-hexahydrocyclopenta[h]chromene-3,7-dione
• CAS: 919788-02-6
• 化学式: C₁₇H₂₂O₄
• 分子量: 290.359
• InChiKey: UFHNRPGLRDOLMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3a-Methyl-6-(3-oxo-butyl)-1,2,4,5,9a,9b-hexahydro-3aH-9-oxa-cyclopenta[a]naphthalene-3,7-dione 在 sodium methylate 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 1.0h， 以1.03 g的产率得到
  参考文献：
  名称：

  Stereoselective synthesis of rac-(8R,13S,14S)-7-oxa-estra-4,9-diene-3,17-dione

  摘要：

  The first synthesis of a novel oxa-steroid, rac-(8R,13S,14S)-7-oxa-estra-4,9-diene-3,17-dione has been achieved via stereoselective catalytic hydrogenation of the tetra-substituted indene intermediate, whose structure was confirmed by X-ray crystallography. In contrast to the previous reports of similar indene systems, it was found that catalytic hydrogenation of indenes with a large substituent at the C-2 position and a bulky beta-oriented protective group at the C-6 position resulted in cis-indanes instead of trans-indanes. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2006.10.098
• 作为产物：
  描述：

  2,6-庚二酮 在 palladium on activated charcoal 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 氢气 、 sodium methylate 、 吡啶盐酸盐 、 碳酸氢钠 、 potassium carbonate 、 氯化铵 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 丙酮 、 甲苯 、 苯 为溶剂， 反应 80.0h， 生成 3a-Methyl-6-(3-oxo-butyl)-1,2,4,5,9a,9b-hexahydro-3aH-9-oxa-cyclopenta[a]naphthalene-3,7-dione
  参考文献：
  名称：

  Stereoselective synthesis of rac-(8R,13S,14S)-7-oxa-estra-4,9-diene-3,17-dione

  摘要：

  The first synthesis of a novel oxa-steroid, rac-(8R,13S,14S)-7-oxa-estra-4,9-diene-3,17-dione has been achieved via stereoselective catalytic hydrogenation of the tetra-substituted indene intermediate, whose structure was confirmed by X-ray crystallography. In contrast to the previous reports of similar indene systems, it was found that catalytic hydrogenation of indenes with a large substituent at the C-2 position and a bulky beta-oriented protective group at the C-6 position resulted in cis-indanes instead of trans-indanes. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2006.10.098

文献信息

• OXA-STEROIDS DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS
  申请人：Kang Fu-An

  公开号：US20070197635A1

  公开（公告）日：2007-08-23

  The present invention is directed to novel 7-oxa-estra-4,9-diene-3,17-dione derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor.

  本发明涉及新颖的7-氧杂雌甾-4,9-二烯-3,17-二酮衍生物，含有它们的药物组合物以及它们在治疗至少受孕激素或糖皮质激素受体调节的疾病和症状中的应用。
• Oxa-steroids derivatives as selective progesterone receptor modulators
  申请人：Janssen Pharmaceutica N.V.

  公开号：US07763648B2

  公开（公告）日：2010-07-27

  The present invention is directed to 7 oxa-estra-4,9-diene-3,17-dione derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor.

  本发明涉及7氧杂雌甾-4,9-二烯-3,17-二酮衍生物，包含它们的制药组合物以及它们在治疗至少受孕激素或糖皮质激素受体调节的疾病和病况中的用途。
• US7763648B2
  申请人：——

  公开号：US7763648B2

  公开（公告）日：2010-07-27
• [EN] OXA-STEROIDS DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS OXA-STÉROÏDES COMME MODULATEURS SÉLECTIFS DU RÉCEPTEUR PROGESTÉRONE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2007098388A2

  公开（公告）日：2007-08-30

  [EN] The present invention is directed to novel 7-oxa-estra-4,9-diene-3,17-dione derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor.
  [FR] La présente invention concerne de nouveaux dérivés 7-oxa-estra-4,9-diène-3,17-dione, des compositions pharmaceutiques qui les contiennent et leur utilisation pour traiter des troubles et des affections modulés par au moins un récepteur progestérone ou glucocorticoïde.